Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2018

View Archived Issues

TGF-beta inhibition restores regeneration in acute liver injury

Discovery of a druggable target for traumatic brain injury

Sumitomo Dainippon Pharma divulges dopamine D1/D2 and/or 5-HT2A receptor antagonists

Biogen patents nuclear factor erythroid 2-related factor 2 activators

Novel animal model of glaucoma created using tree shrews

New lysine-specific histone demethylase 1A inhibitors identified at Medshine Discovery

Elevated FGF23, a causative factor in the development of renal anemia and iron deficiency

Lilly discovers N-Acetyl-beta-D-glucosaminidase inhibitors

FDA approves Opdivo for metastatic SCLC that has progressed after platinum-based chemotherapy

GlaxoSmithKline describes discovery of DNMT1 inhibitors at fall ACS National Meeting

FDA places partial clinical hold on Study OX1222 of OXi-4503

Target of rapamycin complex 1 inhibition improves immune function in elderly subjects

Immunocore initiates phase I study of IMCnyeso under GSK collaboration

Tumors in brain lead to T cells in bone

Vaccinations initiated in first-in-human trial of novel attenuated Zika vaccine

Let there be no light damage

FDA approves Eylea injection sBLA in wet AMD

European clearance for phase II study of SENS-401 for sudden sensorineuronal hearing loss

Celleron enrolls first patient in phase Ib/II study of CXD-101 with nivolumab for colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...